Staphylococcus aureus bacteraemia (SAB) is a clinically heterogeneous disease. The ability to identify sub-groups of patients with shared traits (subphenotypes) is an unmet need to allow patient stratification for clinical management and research. We have reproducibly identified distinct SAB subphenotypes using routinely collected clinical data (Swets et al, Clin Infect Dis 2024;79:1153-61):
(A) SAB associated with older age and comorbidity
(B) nosocomial intravenouscatheter-associated SAB in younger people without comorbidity
(C) community-acquired metastatic SAB
(D) SAB associated with chronic kidneydisease and haemodialysis
(E) SAB associated with injection drug use.
The SNAPstrat sub-study will determine if these subphenotypes can be identified amongst patients included in the trial, then determine if differential treatment effects exist for the trial interventions when patients are stratified by subphenotype membership.
Lead Investigator: Dr. Clark Russell, University of Edinburgh (clark.russell@ed.ac.uk)
C-SNAP: Evaluating the prevalence of vitamin C deficiency and plasma vitamin C level decay in a prospective sample of patients with Staphylococcus aureus bacteraemia enrolled in the SNAP trial
Cefazolin Versus Penicillin for Penicillin-Susceptible Staphylococcus aureus Bacteremia: A Secondary Analysis of the SNAP Backbone Trials
Combination Cefazolin with Ertapenem for methicillin-susceptible Staphylococcus aureus bacteremia.
A Versatile Analyte to Monitor Complications and Guide Treatment Duration in Staphylococcus aureus Bacteremia
Staphylococcus aureus Network: ultrasound for diagnosis of endovascular disease in Paediatrics and Youth
